A Case of Amelanotic Melanoma in the Setting of Cemiplimab Therapy for Invasive Squamous Cell Carcinoma

Cemiplimab is the first PD-1 inhibitor approved in United States for treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (SCC) and basal (BCC), but not melanoma. We describe a case amelanotic melanoma (AM) developing patient on cemiplimab therapy invasive SCC. Cutaneous AM rare subtype that shows little no melanin pigmentation clinical histological examination thus often leading to high misdiagnosis rate. Physicians should consider atypical presentations melanoma, including during surveillance patients managed with immune checkpoint therapy.